Depei Wu
YOU?
Author Swipe
View article: CSF1R modulates megakaryopoiesis by targeting RUNX1 in immune thrombocytopenia
CSF1R modulates megakaryopoiesis by targeting RUNX1 in immune thrombocytopenia Open
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by platelet destruction and defective megakaryopoiesis. However, the mechanisms underlying megakaryocyte (MK) dysfunction in ITP remain unclear. To address this…
View article: Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study
Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study Open
Chronic graft-versus-host disease (cGVHD) is a major complication for long-term survivors after hematopoietic cell transplantation (HCT). Bronchiolitis obliterans syndrome (BOS) is the crucial manifestation of lung cGVHD. Ruxolitinib has b…
View article: A phase 2 trial of a “sandwich” strategy: Sequential CD22/CD19 chimeric antigen receptor T‐cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome–negative B‐cell acute lymphoblastic leukemia
A phase 2 trial of a “sandwich” strategy: Sequential CD22/CD19 chimeric antigen receptor T‐cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome–negative B‐cell acute lymphoblastic leukemia Open
Background The relapse after chimeric antigen receptor (CAR) T‐cell therapy remains a critical challenge, and the optimal timing and treatment strategies for CAR T urgently need to be explored. Autologous hematopoietic stem cell transplant…
View article: The MTORC1 signaling pathway related gene POLR3G serves as a potential prognostic biomarker in Hepatocellular Carcinoma
The MTORC1 signaling pathway related gene POLR3G serves as a potential prognostic biomarker in Hepatocellular Carcinoma Open
This study aims to investigate the prognostic significance and potential biological functions of the MTORC1 signaling pathway-associated gene POLR3G in Hepatocellular carcinoma (HCC). A prognostic risk model for HCC was developed by integr…
View article: HLF gene is a poor prognostic factor in acute myeloid leukemia patients with FLT3-ITD/NPM1 mutations undergoing hematopoietic transplantation
HLF gene is a poor prognostic factor in acute myeloid leukemia patients with FLT3-ITD/NPM1 mutations undergoing hematopoietic transplantation Open
Acute myeloid leukemia (AML) patients with FLT3 -ITD mutations were benefit from hematopoietic cell transplantation (HSCT) in the first complete remission. Previous research suggested that newly diagnosed AML patients with high allelic rat…
View article: Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT
Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT Open
ClinicalTrials.gov, ChiCTR2300067593. Registered January 12, 2013.
View article: Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China
Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China Open
Purpose Patients afflicted with hematological diseases are at an elevated risk of infection, with the potential for the development of sepsis. This study aims to analyze the effectiveness and safety of colistimethate sodium (CMS) in the ma…
View article: Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy
Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy Open
Multiple myeloma (MM) is a hematological malignancy that poses significant treatment challenges due to its heterogeneity and propensity for relapse and progression. In the last two decades, the therapeutic landscape of MM has changed drama…
View article: Impact of ETV6 mutations on clinical outcomes in acute myeloid leukemia: a real-world retrospective cohort study
Impact of ETV6 mutations on clinical outcomes in acute myeloid leukemia: a real-world retrospective cohort study Open
As a member of the ETS family, ETV6 has been demonstrated to be implicated with the molecular etiology of various hematopoietic diseases. However, the clinical impact of ETV6 mutations (ETV6mut) in acute myeloid leukemia (AML) remains uncl…
View article: [Clinical study on intravenous human immunoglobulin (pH4) for hypogammaglobulinemia and infection risk following CD20 monoclonal antibody therapy in patients with B-cell non-Hodgkin lymphoma].
[Clinical study on intravenous human immunoglobulin (pH4) for hypogammaglobulinemia and infection risk following CD20 monoclonal antibody therapy in patients with B-cell non-Hodgkin lymphoma]. Open
Objective: To observe the effect of intravenous human immunoglobulin (pH4) (IVIg) on total immunoglobulin (Ig) levels in patients with B-cell non-Hodgkin lymphoma (NHL) and to evaluate its clinical efficacy in ameliorating hypogammaglobuli…
View article: Supplementary Table S2 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Supplementary Table S2 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Complete remissions in subpopulations by assigned treatment group
View article: Supplementary Table S1 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Supplementary Table S1 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Representativeness of Study Participants
View article: Supplementary Table S5 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Supplementary Table S5 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Hematologic and non-hematologic toxicity related to induction chemotherapy
View article: Supplementary Table S3 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Supplementary Table S3 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Measurable residual disease (MRD) response analysis
View article: Supplementary Table S4 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Supplementary Table S4 from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Survival analysis
View article: Data from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
Data from Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with <i>De Novo</i> Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial Open
Purpose:To assess the efficacy and safety of an induction regimen composed of idarubicin, cytarabine, and cladribine (IAC) in patients with de novo acute myeloid leukemia (AML).Patients and Methods:Adult patients with newly diagnosed AML w…
View article: Hypermethylation of DNA impairs megakaryogenesis in delayed platelet recovery after allogeneic hematopoietic stem cell transplantation
Hypermethylation of DNA impairs megakaryogenesis in delayed platelet recovery after allogeneic hematopoietic stem cell transplantation Open
Delayed platelet recovery (DPR) is a common and complex complication of hematopoietic stem cell transplantation (HSCT) with unclear mechanisms and poor patient outcomes. Emerging evidence suggests that impaired megakaryogenesis plays a cri…
View article: Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study
Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study Open
The multi-center randomized phase 3 NHL-004 study compared etoposide, dexamethasone and pegaspargase (ESA) versus methotrexate, etoposide, dexamethasone and pegaspargase (MESA) regimen, combined with sandwiched radiotherapy, in newly diagn…
View article: Raffinose-metabolizing bacteria impair radiation-associated hematopoietic recovery <i>via</i> the bile acid/FXR/NF-κB signaling pathway
Raffinose-metabolizing bacteria impair radiation-associated hematopoietic recovery <i>via</i> the bile acid/FXR/NF-κB signaling pathway Open
Radiation-associated hematopoietic recovery (RAHR) is critical for mitigating lethal complications of acute radiation syndrome (ARS), yet therapeutic strategies remain limited. Through integrated multi-omics analysis of a total body irradi…
View article: Protein disulfide isomerase is essential for osteoblast differentiation in mice
Protein disulfide isomerase is essential for osteoblast differentiation in mice Open
Protein disulfide isomerase (PDI) is an oxidoreductase responsible for the formation, reduction and isomerization of disulfide bonds of nascent proteins in endoplasmic reticulum (ER). So far, the role of PDI in bone biology has never been …
View article: Exploration of risk factors and characteristics of COVID-19 infection among patients with hematological malignancies in Suzhou, China: a retrospective study
Exploration of risk factors and characteristics of COVID-19 infection among patients with hematological malignancies in Suzhou, China: a retrospective study Open
Background and aim Patients diagnosed with cancer, particularly those with hematologic malignancies, frequently exhibit a state of immunosuppression. Currently, there remains a scarcity of dependable biomarkers for assessing the severity o…
View article: Venetoclax in combination with hypomethylating agents in newly diagnosed and relapsed <i>CBF</i>β<i>::MYH11+</i> acute myeloid leukemia
Venetoclax in combination with hypomethylating agents in newly diagnosed and relapsed <i>CBF</i>β<i>::MYH11+</i> acute myeloid leukemia Open
Not available.